Pages that link to "Q34342939"

The following pages link to Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease (Q34342939):

Displaying 49 items.

• Functional recovery in parkinsonian monkeys treated with GDNF (Q24312738) (← links)
• Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys (Q28373813) (← links)
• Potential future neuroprotective therapies for neurodegenerative disorders and stroke (Q33687436) (← links)
• Parkinson's disease management: towards a new paradigm (Q33714139) (← links)
• Functional changes of the basal ganglia circuitry in Parkinson's disease. (Q33924857) (← links)
• Current discoveries on the cognitive effects of antiepileptic drugs (Q33999483) (← links)
• Remacemide: current status and clinical applications (Q34074824) (← links)
• Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases (Q34296136) (← links)
• Glutamate receptors and Parkinson's disease: opportunities for intervention (Q35107721) (← links)
• Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates (Q35885612) (← links)
• Activation of presynaptic kainate receptors suppresses GABAergic synaptic transmission in the rat globus pallidus (Q36328049) (← links)
• Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis (Q37315448) (← links)
• Glutamate receptors as therapeutic targets for Parkinson's disease (Q37585401) (← links)
• Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. (Q40053132) (← links)
• Clinical potential for the use of neuroprotective agents. A brief overview (Q40374456) (← links)
• Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride (Q40374501) (← links)
• Exitatory Amino Acids in Health and Disease (Q40434479) (← links)
• Glutamate and Parkinson's disease (Q41056504) (← links)
• Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? (Q41107509) (← links)
• Early detection of Parkinson's disease. Implications for treatment (Q41172466) (← links)
• Remacemide hydrochloride: a novel antiepileptic agent (Q41467786) (← links)
• Differential effects of bilateral dopamine depletion in neonatal and adult rats (Q41509252) (← links)
• Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. (Q42439060) (← links)
• Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. (Q42468515) (← links)
• Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. (Q42486829) (← links)
• GABA(B) receptors in the centromedian/parafascicular thalamic nuclear complex: an ultrastructural analysis of GABA(B)R1 and GABA(B)R2 in the monkey thalamus (Q42492123) (← links)
• The treatment of spinocerebellar ataxias: facts and hypotheses (Q42687828) (← links)
• Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease (Q43507658) (← links)
• Co-localization of AMPA-type glutamate receptor immunoreactivity in neurons of the rat subthalamic nucleus (Q43548458) (← links)
• Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice (Q43583632) (← links)
• A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease (Q44011628) (← links)
• Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons. (Q44257112) (← links)
• Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration (Q44365318) (← links)
• Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study. (Q44535353) (← links)
• Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys (Q44535361) (← links)
• Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity (Q44662741) (← links)
• Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia (Q48174974) (← links)
• A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease (Q48199227) (← links)
• The effects of temperature and scopolamine on N-methyl-D-aspartate antagonist-induced neuronal necrosis in the rat. (Q48247551) (← links)
• Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits (Q48271271) (← links)
• Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration (Q48345238) (← links)
• Induction of heat-shock protein (HSP72) in the cingulate and retrosplenial cortex by drugs that antagonize the effects of excitatory amino acids (Q48696115) (← links)
• Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients (Q57480485) (← links)
• Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites (Q57480488) (← links)
• Antiparkinsonian effect of flupirtine in monoamine-depleted rats (Q71542501) (← links)
• Mutual interaction between remacemide hydrochloride and phenytoin (Q73206511) (← links)
• Effects of dopaminergic agents and of an NMDA receptor antagonist on motor coordination in Lurcher mutant mice (Q77890621) (← links)
• Restoration and putative protection in Parkinsonism (Q79760124) (← links)
• Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy (Q81554223) (← links)